To our knowledge, this is the first study to examine peripheral IDO levels in first-episode drug-naive patients with schizophrenia and to explore the correlation between inflammatory molecules and IDO following treatment with the COX2 inhibitor, celecoxib. Here, PTGS2 is linked to schizophrenia.